Carelol

MEDICAL GRAND ROUNDS SOUTHWESTERN MEDICAL SCHOOL UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT DALLAS JANUARY 15, 1987

The Relationship Between Hypertension and Coronary Heart Disease: Is Treatment for Better or for Worse?

THOMAS C. SMITHERMAN, M.D.

TABLE OF CONTENTS

INTRODUCTION

Hypertension and the Risks of Coronary Heart Disease The Importance of Left Ventricular Hypertrophy Questions Raised in this Review

CLINICAL TRIALS WITH PLACEBO OR NO THERAPY CONTROLS

Veterans Administration Cooperative Study (VA)
Public Health Service Trial (PHS)
Oslo Trial
Australian Trial
European Working Party on High Blood Pressure
 in the Elderly (EWPHE) Trial
Medical Research Council of the U.K. Trial (MRC)

CLINICAL TRIALS WITH CUSTOMARY CARE IN THE COMMUNITY CONTROLS

Hypertension Detection and Follow-up Program (HDFP) Multiple Risk Factor Intervention Trial (MRFIT)

WHY IS THE REDUCTION IN CORONARY EVENTS WITH ANTIHYPERTENSIVE THERAPY ONLY ONE-FIFTH THE MAXIMUM EXPECTED BENEFIT?

Diminished Power of the Studies to Detect Endpoints with Statistical Significance

Could Treatment in Some Patients Be Deleterious? Atherogenic Effects on Serum Lipids Diuretics, Hypokalemia, and VPDs Is Antihypertensive Therapy in Patients with ECG Abnormalities Potentially Deleterious? Diminished Coronary Arterial Flow Reserve in Left Ventricular Hypertrophy and Coronary Heart Disease: Could This Be Related to Possible Deleterious Effects of Antihypertensive Therapy?

ARE ALL MEANS OF EQUAL BLOOD PRESSURE LOWERING OF EQUAL BENEFIT IN PREVENTING CHD MORTALITY AND MORBIDITY?

Prevention of LVH and Effecting Its Regression Cardiac Dysfunction in Hypertension and Its Treatment Beta-Blocker-Based vs. Non-Beta-Blocker-Based Therapy Trials Medical Research Council Of the U.K. Trial (MRC) International Prospective Primary Prevention Study (IPPPSH)

A CONCISE SUMMARY

CONCLUSIONS AND RECOMMENDATIONS

REFERENCES

INTRODUCTION

Hypertension is a major risk factor for the development of coronary heart disease (CHD) and its complications, angina pectoris, heart attack, and sudden cardiac death, along with other types of cardiovascular morbidity and mortality. (P1, K1, K2, K3, K4). Data from the Pooling Project (P1), a pooling of 5 epidemiologic studies which include the results of 7065 men from age 40-59, are shown in Table 1. These men were free of definite coronary heart disease upon entry into the study. The rate of deaths from all causes, the death rate from coronary heart disease, and the rate of coronary events, non-fatal MI plus coronary heart disease deaths are shown with respect to diastolic blood pressure at the study baseline. Mild hypertension, with a diastolic blood pressure of 90-104 mm Hg increases coronary event rate 75% compared to men with diastolic blood pressure less than 80 mm Hg. Moderate hypertension, with a diastolic blood pressure of 105-114 mm Hg increases the coronary event rate by 88%. If hypertension is complicated by left ventricular hypertrophy (LVH) as judged by highly specific but not very sensitive ECG criteria (LVH-ECG) the prognosis for coronary heart disease is ominous. LVH-ECG including repolarization abnormalities (ST-segment and Twave changes) is associated with a six-fold increase in mortality from coronary heart disease. (K5,K6). Increased left ventricular voltage alone, without repolarization abnormalities, triples the risk for coronary events. (K6). Detection of LVH by echocardiography (LVH-ECHO) has proved to be an excellent means of detecting LVH and a valuable adjunct to the ECG. (R1,D1,D2,D3,S1,W1). In a recent study of 140 hypertensive men followed for a mean of 4.8 years, detection of LVH-ECHO was associated with an incidence of coronary events (14%) almost 3 times as high as in hypertensive men without

TABLE 1

MORTALITY AND MORBIDITY RELATED TO BLOOD PRESSURE IN MEN 40 - 59

WITHOUT OVERT CORONARY HEART DISEASE (CHD)

Baseline	No .	Dea	ath 8	Core	onary Jent	All- De	Cause aths
Diastolic Blood Pressure	Subjects	Rate *	% Increase	Rate *.	Z Increase	Rate *	% Increase
<80	1575	32	ï	64		84	I.
80-89	2736	44	37.5	87	36	103	23
90-104	2254	56	75	112	75	133	58
105-114	339	96	200	168	167	209	149
² 115	161	86	206	239	273	272	224

* Events per 1000 Patients Data from the Pooling Project (P1) LVH-ECHO (5%). (C1). The prevalence of hypertension in the US is high, afflicting 30% of the population. Mild-to-moderate diastolic hypertension, from 90 to 114 mm Hg, is the commonest, afflicting about 20% of the population. (J2).

One would predict, on the basis of these overwhelming epidemiological data, that treatment of hypertensive patients should be associated with a clear-cut decrease in morbidity and mortality from coronary heart disease along with a decrease in the overall toll from other cardiovascular complications including development of LVH, stroke, cerebrovascular deaths, congestive heart failure, and accelerated hypertension. But such an effect on coronary heart disease endpoints from anti-hypertensive therapy has been hard to show. The results of clinical trials have often been perplexing and sometimes have seemed to be contradictory. Different interpretations of the data have led to differing, sometimes contradictory, conclusions and recommendations. Considerable new data have been presented in the last two years. The purpose of this review is to take a fresh look at the status of coronary heart disease and anti-hypertensive treatment. I will look for answers to three questions:

- Does anti-hypertensive therapy of mild-to-moderate hypertension reduce mobidity and mortality from coronary heart disease?
- 2. Which hypertensive patients should be treated with the aim of reducing the toll from coronary heart disease?
- 3. Does the type of antihypertensive therapy matter?

For this review, I have limited consideration of the large clinical trials to those studies that included at least several hundred subjects and that had a mean follow-up period of at least 3 years. There are 10 such studies. One of them, the Heart Attack Primary Prevention in Hypertension or HAPPHY Study, was just presented at a meeting in the fall of 1986. A full

report has not been published. Therefore, the data that I will discuss are derived for the most part from nine clinical trials. Six trials were controlled with a placebo or no-treatment group. Two trials compared the results of carefully conducted antihypertensive treatment with usual care in the community. Two trials, one with a placebo group as well, compared therapy based on diuretic therapy with therapy based on beta-blockers.

CLINICAL TRIALS WITH PLACEBO OR NO-THERAPY CONTROLS

Table 2 outlines the design features of the six trials that compared anti-hypertensive therapy with placebo administration or with no therapy. The first of these, the Veterans Administration Cooperative Study (VA), that was first published in 1970, is the classic well-designed study on the efficacy of treatment of mild-to-moderate hypertension. (V1, V2). It came three years after the report from the same group of investigators on the remarkable effectiveness of treatment of severe hypertension. (V3). The most recent reports, from the European Working Party on High Blood Pressure in the Elderly (EWPHE) (A1) and the study supported by the Medical Research Council of the United Kingdom (MRC) (M1), were published just over a year ago.

With the single exception of the EWPHE trial, the subjects studied were predominantly middle-aged, the mean age ranging from 44.4 in the Public Health Service Hospitals Cooperative Study (PHS) (S2), to 52.8 in the VA trial. The EWPHE trial enrolled only patients aged 60 and older. The mean age was 72.

All the patients in the VA and Oslo (H1) trials were male. Men comprised 80% of the PHS trial, 63% of the Australian Therapeutic Trial in Mild Hypertension (Australian) (M2), and 52% of the MRC trial. In only one trial, the EWPHE trial, were men in the minority, making up 30% of the total. The sex ratio is important in analyzing the trials, for even in hypertensive patients, coronary heart disease endpoints are far commoner in men than women.

 These data should b Patients with blood treated with unspec This trial had two 	Net change in DBP, Trested-control (mmHg)		Drugs, Daily Dose ⁴	Control	Yrs, Follow-up _y Range, Mean	Size	LVH, prevalence 1	Cardiac Disease Exclusions	Blood Pressure	% Men	Population Age, Range, Mean	19
oe used cautiously beca d glucose higher than d ified other regimens. separate treatment lin	-19	II. HDRZ, 150	I. HCTZ, 100 Reserpine, 0.2 HDRZ, 75	DB, placebo	1-5.5, 3.8	380	162	Severe Only	90-114, D	100	24-75, 52.8	VA 170, 1972
ause there was no unif 7.2 mmol/L were given mbs, diuretic-based vs	-10		I. CTZ, 1000 Rauwolfia Sepentina, 200	DB, placebo	7-10, 7+	389	16% (7 voltage only)	CHF, Previous MI, Angina, positive exercise test	90-114, D	80	21-55, 44.4	PHS 1977
orm definition of LVH amon only a Phase II drug. 72 . beta-blocker-based.	-10	II. AMD, 500- 1000 or Prop, 80-320	I. HCTZ, 50 ²	Open, No Therapy	5-6.5, 5.5	785	37% (voltage) 0% marked LVH	CHF, any known coronary heart disease, cardiovascular disease, marked LVH	95-99, D or 150-179, S	100	40-49, 45.3	01.50 1980, 1984
g the studies. patients vere	III. HDRZ, ? or Clonidine, ? -6	II. AND, 7 or PROP, 7 or Pindolol, 7	I. CTZ, 500-1000	SB, placebo	7, 4.0	3,427	7	CHF, History of angina, Myocardial Ischemia on ECG, MI within 3 months	95-109, D	63	30-69, 50.5	AUSTRALIAN 1980
	II. АНЪ, 250-2000 —8		I. HCTZ, 25-50 Triamterene, 50-100	DB, placebo	7-7, 4.6	840	-	CHP	90-119, D and 160-239, S	30	60-7, 72	EUROPEAN Norking party 1985
	II. A. AMD, ? B. AMD,? or Guamethidine, ? -5.5	I. A. Bendrofluazide, 10 ³ B. PROP, Up to 240		SB, placebo	7-5, 4.9	17, 354	0.37 (voltage 6 repolarization)	CPF, MI within 3 mos, Angina	90-109, D	52	35-64, 52	NRC 1985

ABBREVIATIONS: DB = double blind, SB = single blind, HCTZ = hydrochlorthiazide, HDRZ = Hydralazine, CTZ = chlorthiazide, AMD = alpha methyl DOPA, D = diastolic, S = systolic, DBP = diastolic blood pressure, PROP = propranolol, CHF = congestive heart failure, MI = myocardial infarction, LVH = left ventricular hypertrophy, 7 = unknown: not specified or not stated.

TABLE 2

MILD-TO-MODERATE HYPERTENSION AND CORONARY HEART DISEASE

DESIGN FEATURES OF SIX FLACEBO OR NO-THERAPY CONTROLLED TRIALS The greater the proportion of men in such studies, the greater power it has for examining the differences in the rates of coronary events.

With the exception of the Oslo trial, subjects were enrolled with blood pressure elevations that ranged from mild to moderate with the lower limit of diastolic blood pressure ranging from 90 to 95 mm Hg and the upper limit from 109 to 119 mm Hg. The Oslo trial was confined to a somewhat milder group of hypertensives entering only patients with diastolic pressures of 95 to 99 mm Hg or systolic pressures of 150 to 179 mm Hg.

The VA trial was the most liberal in entering patients with existing cardiac disease. Only patients with severe cardiac involvement were excluded. The other trials excluded patients with any active cardiac disease. The PHS and Oslo Studies excluded patients with <u>any</u> cardiac disease except left ventricular hypertrophy. The degree of cardiac damage at the study baseline is also an important issue to keep in mind when analyzing these studies. One would expect a larger number of coronary endpoints during follow-up in patients with pre-existing cardiac disease than in patients without it.

The VA, PHS, Oslo, and EWPHE Studies were moderate in size, each enrolling several hundred patients. The Australian trial was much larger, enrolling almost 3.5 thousand subjects. The MRC trial was huge, enrolling over 17,000 hypertensives.

The time of active follow-up was only moderately long in all of these studies. Follow-up ranged from a mean of 3.8 years in the VA study to over 7 years in the PHS Study. In the other studies mean follow-up was 4 to 5.5 years.

All but the PHS study utilized a step-care approach to treatment. In that study all patients received diuretic and sympatholytic therapy. The VA study utilized a step-care approach only in a limited sense. All patients

received diuretic, sympatholytic and vasodilator therapy. The second step was merely an increase in vasodilator dose. Three studies utilized a step-care approach similar to that commonly used in clinical practice now: diuretic therapy as step 1 and addition of sympatholytic therapy as step 2. The Australian trial had a third step allowing addition of vasodilator or switch to yet another sympatholytic agent. The MRC trial had two separate treatment modes. In the first, step one was beta-blocker and step two was addition of a central sympatholytic. In the other active treatment group, step one was diuretic and step two was addition of a peripheral or central sympatholytic agent.

The net decrease in diastolic blood pressure in the treated group, that is the drop in the treated group less the drop in the control group, was greatest by far in the VA trial, -19 mm Hg. It was -10 mm Hg in the PHS and Oslo trials, -8 mm Hg in the EWPHE trial, -6 mm Hg. In the Australian trial and only -5.5 mm Hg in the huge MRC trial. This rather small net treatment effect in the MRC trial has been the subject of discussion and criticism. There is a dual reason. The drop in blood pressure in the treatment groups was less than hoped for and the drop in the placebo group was greater than expected. A detailed analysis of the findings of these studies other than on coronary heart disease is beyond the scope of this review, but a brief discussion of these findings is necessary to put the coronary heart disease findings into proper perspective. Protection against stroke, congestive heart failure, accelerated hypertension, and development of left ventricular hypertrophy have been found rather uniformly. The Australian and EWPHE trials also showed a statistically significant reduction in all cardiovascular disease deaths. There was a strong trend in that direction in the VA trial.

Table 3 outlines the results of these six trials on coronary heart

EVENT 3

WILD-TO-MODERATE HYPERTENSION AND COROMARY HEART DISEASE

NORBIDITY AND NORTALITY FINDINGS OF SIX FLACEBO

OR NO-THERAPY CONTROLLED TRIALS

	T(X)	C(Z)	X Change¶	T(Z)	C(X)	X Change¶	T(X)	C(X)	X Change¶	T(Z)	C(Z)	Z Change¶	EUROPEAN T(Z)	WORKING P C(Z)	AATT I Change¶	I(Z)
Non-Patal MI	5(2.7)	2(1.0)	+161	7(3.6)	6(3.1)	+18	8(2.0)	8(2.1)	-1	28(1.6)	22(1.3)	+26	19	12	+ca.56*	116(1-3)
Cardiac Death	6(3.2)	11(5.7)	5	2(1.0)	4(2.0)	-49	6(1.5)	2(0.5)	+180	5(0.3)	11(0.6)	-55, p=0.051	29(7.0)	47(11.1)	-37.p=0.036	106(1.2)
Total Coronary Events	11(5.9)	13(6.7)	-13	9(4.7)	10(5.1)	-5	14(3.4)	10(2.6)	•31	33(1.9)	33(1.9)	7	48(11.5)	59(13.9)	-17	222(2.6)
No. Subjects	186	194		193	196		406	379		1721	1706		416	476		

. The non-fatal NI data in this trial were presented only according to events on randomized therapy. Data according to the intention to treat analysis were not provided. The approximate Z change was calculated from the attend rates (number of patients having an event per 1000 patient years under observation) of 9 for the control group and 14 for the treatment group.

92 change = Control - Treatment/Control.

ABDREVIATIONS: T = Treatment, C = Control

	8654	8700		424	416	
٢	234(2.7)	222(2.6)	-17	59(13.9)	48(11.5)	
é	97(1.1)	106(1.2)	-37,p=0.036	47(11.1)	29(7.0)	51
-16	137(1.6)	116(1.3)	+cs.56*	12	19	
Z Change	C(X)	I(Z)	PARTY I Change ¶	MORE ING C(Z)	EUROFEAN T(X)	

disease endpoints, non-fatal MI, coronary heart disease death, and the combination of these two, referred to as coronary events. The results on coronary heart disease endpoints are much more difficult to analyze. In these six trials, there were only two endpoints that were statistically significant or nearly so. In the EWPHE trial, coronary heart disease deaths were decreased 37% by antihypertensive therapy (p=0.036). The same endpoint was reduced 55% in the Australian trial (p=0.051). (The Australian trial was stopped at that point because total mortality, all cardiovascular causes of death, and all cardiovascular endpoints were significantly reduced by antihypertensive therapy). There were similar strong trends in the VA and PHS studies. In reviewing these six studies, there is no apparent trend favoring a reduction in non-fatal MI. Therefore, in reviewing the coronary event rate, only a trend favoring a rather small, perhaps 10% reduction emerges, which owes largely to a reduction in the coronary death rate.

CLINICAL TRIALS WITH CUSTOMARY CARE IN THE COMMUNITY CONTROLS

In the early 1970's, the National Heart, Lung, and Blood Institute assembled panels to make recommendations on the need and feasibility of trials to address risk factors for cardiovascular disease. One of the major issues was whether risk factor modification could lower mortality and morbidity from coronary heart disease. From the recommendations of these panels came two very large studies that compared special intervention in special clinical centers with customary care in the community. The first of these, the hypertension detection and follow-up program (HDFP) (H2,H3,H4,H5), restricted their efforts to correction of hypertension. The second, the Multiple Risk Factor Intervention Trial (MRFIT) (M3,G1), was designed to treat hypertension, and to make efforts to diminish tobacco smoking and to lower serum cholesterol by nutritional changes. The aim was to identify men in the highest decile of

TABLE 4

MILD-TO-MODERATE HYPERTENSION AND CORONARY HEART DISEASE

DESIGN FEATURES OF TWO TRIALS WITH COMMUNITY CARE CONTROLS

	HDFP 1979	۲ 198	RFIT 82, 1985
Population			
age, range, mean	30-69, 51		35-57, 46
% men	54		100
Blood Pressure	90 +,D (Divided into 3 strata)		90 -114, D
Cardiac Disease Exclusions	Severe Only		MI, Angina
LVH, Prevalence	5% (voltage + repolarization)		18% (voltage)
Size	10,940		8,012
Years Follow-up, range, mean	5,?		6-8,7
Control	Referred Care (To Usual Source)		Usual Care
Drugs I.	Chlorthalidone, 25-100 and/or Spironolactone, 25-100 or Triampterene, 50-300	I.	Chlorthalidone, 25-100 or HCTZ, 25-100 or Spironolactone, 50-100 or Triampterene
II.	Reserpine, 0.1-0.25 or AMD, 500-2000	п.	Reserpine, 0.1-0.25 or AMD, 500-2000 or PROP, 80-480
III.	HDRZ, 30-200	ш.	HDRZ, 30-200
IV.	Guanethidine, 10-200	IV.	Guanethidine, 10-200
v.	Other Drugs		
Net change in diastolic BP From baseline Treated-Control (mmHg)	-17 -5		-14 -4

ABEREVIATIONS: Same as for Table 2.

risk for development of coronary heart disease. Sixty-two percent of all patients enrolled were hypertensive. Table 4 outlines some of the design features of these two trials. Like most of the six studies just described, the subjects were mostly middle-aged. The mean age at entry was 51 for HDFP and 46 for MRFIT. Slightly over half of the subjects in HDFP and all of the MRFIT subjects were men. MRFIT limited enrollment to patients with mild to moderate hypertension. HDFP had no upper limit, but there were relatively few patients enrolled with diastolic blood pressure 115 mm Hg or higher. HDFP, like the earlier VA study, excluded subjects with cardiac damage only when it was severe. MRFIT was more conservative; it excluded men with angina or known MI. Both studies were huge. There were almost 11,000 subjects in HDFP and just over 8,000 hypertensive subjects in MRFIT.

The more aggressively treated groups, called stepped care (SC) in HDFP and special intervention (SI) in MRFIT were treated with very similar regimens. The first steps were diuretic therapy. The second steps were addition of sympatholytic therapy. MRFIT, but not HDFP, included a betablocker as a choice along with reserpine and alpha methyl DOPA (AMD). The third steps were addition of vasodilator and the fourth addition of another sympatholytic agent, guanethidine. HDFP had a fifth step of other approved drugs for the few who did not respond to steps 1-4. Both trials succeded in lowering the absolute levels of blood pressure. But the control patients who received customary care in the community [referred care (RC), HDFP; usual care (UC), MRFIT] had a greater drop in blood pressure than had been anticipated when the study was designed, so the net reduction in blood pressure between treatment and control groups was rather small, 5 mm Hg for HDFP and 4 mm Hg for MRFIT. The results of these two trials on coronary heart disease endpoints are shown in Table 5. So far, MRFIT has published only

ABRREVIATIONS: SC = Step (AD = Corr	<pre>* = Rate per 100 Subjects { = Limited to Hypertensi</pre>	No. Subjects	+ECC + Hx + RQ	+ RQ	+ Hx	Death + EOG	Coronary Events		CHD Death	ECC, Hx + RQ	Rose Questionaire (RQ)	History (Hx)	ECC, 0/CS change	Non-Fatal MI				
ped Care, pnary Hea	ve Subjec	4973	431	420	216	159			85	346	320	124	40			No.		
, RC = Refei irt Disease	ts		8.7	8.2	4.2	3.0			1.7	7.0	6.2	2.4	0.7			Rate*	SC	
rred Care, SJ		4949	513	505	275	178			100	413	379	161	41			No.	HDFP R	
[= Specia			10.4	9.8	5.3	ເນ ເມື			2.1	8.3	7.3	3.1	0.8			Rate*	0	
1 Intervention, UC =			-16.3(p=0.004)	-16.3(p=0.004)	-20.8(p=0.008)	-9-1		8	-20.0	-15.7(p=0.02)	-15.1(p=0.03)	-22.6(p=0.03)	-12.5	3	change RCSC/RC	%		
Usual (4019	I	1	I	ı			80	ı	1	I	I			No.	-	
are			1	, r	1	I			1.99	ı	ı	ı	ı			Rate*	SI MR	
		3993	ī	1	١	ı			79	ı	ı	L	ı			No.	FIT.	4
			ı	ı	ı	•			1.98	ı	•	ı	1		U	Rate*	ñ	
			ı	ı	1	ı			+0.5	I	ı	ı	ı		change C-SI/UC	%		1

MILD-TO-MODERATE HYPERTENSION AND CORONARY HEART DISEASE MORBIDITY AND MORTALITY

FINDINGS OF TWO STUDIES WITH ODPHINITY CARE CONTROLS

TABLE 5

mortality data. The death rate was practically identical in SI and UC groups. There were some positive results from HDFP. There were 15 fewer deaths in the SC group than there were in the RC group, a 20% reduction that was not statistically significant. The decline in the incidence of myocardial infarction and coronary events was presented in this study based upon how the information was determined. Sensitive, yet specific detection of MI in a study such as this is quite difficult. Detection of new pathologic Q/QS change on occasional ECGs is very specific but insensitive. Adding cases based upon medical histories and a standardized questionaire (the Rose Questionaire) is likely to be fairly sensitive but less specific. Presumably, however, in a large study such as this, the errors in both groups would be comparable allowing the judicious use of subjective as well as objective analysis for MI detection. There was only one fewer MI by Q/QS criteria on ECG. But when the data are analyzed using subjective criteria for MIs, statistically significant reductions in the MI rate from 16 to 23% were detected. The number of coronary events is similarly affected depending on the way of reckoning MI. With pathologic Q/QS changes on ECG, there were 19 fewer events, a statistically insignificant reduction of 9%, but adding subjective MI detection, the reduction of coronary events ranges from 16 to 21% and was statistically significant.

The HDFP also looked at the incidence of angina in the SC and RC groups. The prevalence of angina at the study baseline in the SC group, 7.6%, was slightly higher than the 7.2% incidence observed in the RC group. But at each of the three blood pressure strata of mild, moderate, and severe hypertension, there were significantly fewer patients experiencing angina in the SC than in the RC groups. The reduction was 15% for mild hypertension, 43% for moderate hypertension, and 54% for severe hypertension. The total reduction was 28%.

There is certainly no entirely satisfactory way to pool the results of these eight trials to get a better overview. Nevertheless, recognizing the hazards, I have simply summed the incidences of non-fatal MI, CHD death, and coronary events in Table 6. Using this approach, there were 10% fewer deaths with therapy and either 8% or 12% fewer coronary events, the former using the HDFP MI incidence limited to Q/QS changes, the latter using all criteria for MI in that trial.

If the angina data from the HDFP were included along with MI as a morbidity endpoint, the overall results favoring therapy would be even stronger.

These are the data available to address the question: Does antihypertensive therapy of mild-to-moderate hypertension reduce morbidity and mortality from coronary heart disease? There is not now a consensus on the answer to that question and debate will doubtless continue. I am prepared, however, to cautiously conclude that the answer is probably positive. I base that conclusion on the following:

- 1. The simultaneous overview of all the trials showing an overall benefit, even if a small one.
- 2. The statistically significant positive findings in the HDFP and the EWPHE trial, and the nearly significant positive findings of the Australian trial.
- 3. The lack of any statistically significant negative findings.

But the benefit a rather disappointingly small one. Assuming that the patients enrolled in these studies were like those of the Pooling Project and had a doubled likelihood of a coronary event, complete amelioration of the excess risk would reduce coronary events by 50%, roughly five times what was found.

TABLE 6

MILD-TO-MODERATE HYPERTENSION AND CORONARY HEART DISEASE

SUMMED RESULTS OF EIGHT TRIALS OF ANTIHYPERTENSIVE THERAPY TO PREVENT CORONARY

HEART DISEASE ENDPOINTS

	No. CHI) Deaths	No. Coronary E	lvents	No.	Subjects
	Т	С	Т	С	Т	C
Trial						
VA	6	11	11	13	18	6 194
PHS	2	4	9	10	19	3 196
OSLO	6	2	14	10	40	6 379
AUSTRALIAN	5	11	33	33	172	1 1706
EWPHE	29	47	48	59	41	6 424
MRC	106	97	2.2.2	234	870	0 8654
MRFIT	80	79	-	-	401	9 3993
HDFP	85	100	431(125)*	513(141)*	497	3 4949
TOTAL DEATHS	319	351			2061	4 20495
%	1.5%	1.7%				
TOTAL CORONARY EVENTS			768(462)*	872(500)*	1659	5 16502
%			4.6%(2.8%)*	5.3%(3.0%)*		
% CHANGE, C-T/C		-9.6%	-12.4%(-8.1%)		*	

* Numbers in parentheses are values if only the MIs objectively documented by pathologic O/OS changes on ECG are included from the HDFP.

ABBREVIATIONS: C = Control, T = Treatment

WHY IS THE REDUCTION IN CORONARY EVENTS WITH ANTIHYPERTENSIVE THERAPY ONLY ONE-FIFTH THE MAXIMUM EXPECTED BENEFIT

A consideration of why the demonstrated reduction in coronary events with antihypertensive therapy is only about one-fifth the maximum expected benefits is a necessary and interesting digression.

There are three major possibilities:

- 1. Anti-hypertensive therapy is only minimally effective in decreasing coronary events.
- 2. The studies, as designed, did not have sufficient power to more frequently detect, with statistical significance differences between the treatment and control groups.
- 3. Treatment, at least in some subgroups, may have been deleterious and thereby masked beneficial effects in other subgroups.

Diminished Power of the Studies to Detect CHD Endpoints with Statistical Significance

Four of the eight studies discussed above were very large. Their size was planned to give them the power to detect, with statistical significance, small changes and two of those studies did so and one almost did. Several things happened to frustrate the plans for the studies' designs and reduced the power of the studies. The mortality and morbidity rates of the control groups were lower than had been anticipated. Blood pressure in the control groups fell more than was anticipated in some studies. It would have made for more powerful studies to include more men and older subjects but the cost of such design would be to make the studies less relevant to women and a younger population.

The complexities of the interactions of the risk factors for coronary heart disease, especially male sex, hypertension, tobacco smoking, hypercholesterolemia and diabetes mellitus also affect the power of trials such as these. The other major complications of hypertension are less

affected by the other risk factors. But to design an intervention trial in the 1970s or even now in an attempt to unravel these complex interactions is impractical and much too costly.

Could Treatment in Some Patients be Deleterious? Atherogenic Effects on Serum Lipids

The possibilities of deleterious treatment effects deserves detailed discussion. The first possibility, adverse treatment effects on serum lipids - causing a more atherogenic pattern - has received wide attention (W5). Diuretic therapy and also beta-blocker therapy - at least beta-blockers without intrinsic sympathomimetic activity - do this. This raises the question that a more atherogenic lipid profile might accelerate the atherosclerotic process and diminish or counterbalance a protective effect of lowering blood pressure. There is no clear resolution of this issue available but there is a consensus that the changes in lipids are much too modest and the treatment periods studied too short to believe that accelerated atherosclerosis was a major confounding influence in these eight clinical trials. Nevertheless, since antihypertensive therapy is often necessary for decades, this issue is an open one and deserves further investigation.

Diuretics, Hypokalemia, and VPD's

A second possible deleterious influence of therapy has also received wide attention. Diuretic therapy with thiazide or thiazide-like diuretics was a fundamental part of anti-hypertensive therapy in each of the studies discussed above except for the group in the MRC trial treated principally with betablockers, and 34% of that group also received supplementary therapy with diuretics. This results in reduced serum potassium levels and increased frequency and complexity of ventricular premature depolarizations (VPDs). The

MRC trial explored this issue extensively (M4, G2). Long-term bendrofluazidetreated patients had significantly more VPDs and more complex VPDs and significantly lower serum potassium levels than placebo patients. Magnesium losses as well as hypokalemia during long-term diuretic therapy have also been suggested to be associated with VPDs. (H6,H7). A causal role of hypokalemia for the increased VPDs in the MRC study cannot be claimed, but the weight of literature regarding VPDs and hypokalemia in patients with heart disease certainly favors a causal role. The relationship between frequent and complex VPDs and sudden death in patients with heart disease is well-established. (R3). Again, we have insufficient data to reach any firm conclusions regarding the power of more frequent or more complex VPDs to diminish or counterbalance beneficial effects of lowering blood pressure in hypertensive patients. Again, there is a consensus that increased VPDs do not have that power, but this issue also remains open and will require more investigation for a firm conclusion. Comparison of beta-blocker-based and non-beta-blockerbased therapy in hypertension speaks to this issue to some degree and is discussed below.

Is Antihypertensive Therapy In Patients

with ECG Abnormalities Potentially Deleterious

A third possible deleterious effect of therapy in a subset of patients was first raised by MRFIT. In this trial, a <u>post hoc</u> analysis of subgroups showed that men with abnormal ECGs at the study baseline who were in the SI group had <u>more</u> CHD deaths than subjects in the UC group. On the other hand, men without ECG abnormalities at the study baseline in the SI group fared better than men in the UC group. (G1). (Table 7). The principal ECG abnormalilty (observed in 41% of cases) was tall R-waves. Atrioventricular or intraventricular conduction defects (observed in 29% of cases), and

	EFFECT OF BO	G ABNORMALLIT	IES AT THE STUDY BAS	ELINE ON OUTCOME	WITH ANTIHY	PERCHANSIVE THERA	PY
	SI SC TREAT	(NRFIT) (HDFP) MENT (OSLO)			UC (MRI RC (HDI FLACEBO (위T) 판) (0SL0)	
	No. Subjects	No * Events	Rate¶	No. Subjects	No.* Events	Rate¶	% Difference C-T/C
MRFIT							
EOG -	2785	44	15.8	2808	58	20.7	-23.5
ECC +	1233	36	29.2	1185	21	17.7	+64.8
HDFP							
ECC -	1650	16	9.7	1659	27	16.3	-40.5
ECC +	981	22	22.4	1063	20	18.8	+19.4
OIBO							
ECC -	273	12	44	225	8	36	+23.6
ECC +	133	ø	60	154	S	32	+85.3
* EVENTS = Coronary Heart 1 EOG during exerc	Deaths for MRFT rise for Oslo.	I and HDFP.	Coronary heart dise	ase deaths, myoc	ardial infarc	tion, and anging	2 + abnormal
¶ Rate = Events per 1000	patients.						
ABBREVIATIONS = SC = Steppe	d Care, RC = Re	ferred Care.	SI = Special Interv	vention, UC = Usu	val Care, CHD	= Coronary Hear	t Disease.

TABLE 7

20

T = Treatment, C = Control.

.

.

repolarization abnormalities (ST-segment deviation or T-wave inversion, observed in 26% of cases) (H8) were the commonest abnormalities. Note that in these subjects, hypertensive heart disease (especially left ventricular hypertrophy) is likely the chief cause of these ECG abnormalities followed by CHD or both disorders.

These findings prompted HDFP to perform a similar <u>post hoc</u> analysis of their data. (H8) They were able to identify 5173 men <u>and women</u> who, other than inclusion of women, were like the subjects of MRFIT. The major ECG abnormalities at the study baseline were similar: tall R waves in 49% of cases, conduction defects in 23% of cases, and repolarization abnormalities in 45% of cases. The overall findings in HDFP, unlike MRFIT, favor antihypertensive therapy in the SC over RC in patients with these ECG abnormalities at the study baseline, but the results, limited to CHD deaths, are similar to although less marked than, those of MRFIT; subjects with baseline ECG abnormalities do worse with SC than do their RC counterparts, but subjects without ECG abnormalities at the study baseline do much better with SC than with RC. (Table 7).

The Oslo study has also carried out a <u>post hoc</u> analysis of their data along somewhat similar lines. (H9). Since that study had a much smaller number of participants, the investigators had to compare the pooled occurrence of several CHD endpoints instead of only CHD death. These endpoints were CHD death, MI, and angina pectoris with an abnormal ECG during exercise. Recall that of all of the eight studies, the Oslo trial had the most negative results. Even with this analysis, there were no trends favoring therapy, even in the group without ECG abnormalities at baseline, but in the group with ECG abnormalities at baseline, the treatment group fared much worse than the placebo group. (Table 7).

There seems to be a consensus that there may be some substance to this issue and that it deserves further investigation. These observations, if correct, certainly beg for reasons why. Again the issue of diuretic therapy, hypokalemia, and VPDs arises. It is quite likely that patients with ECG abnormalities at entry into the study had more advanced cardiac disease than did their counterparts without ECG abnormalilties. It has been observed that VPDs in the presence of heart disease are associated with a greater risk of sudden death than VPDs in its absence. (B5).

Diminished Coronary Arterial Flow Reserve in Left Ventricular Hypertrophy and CHD. Could this be Related to Possible Deleterious Effects of Antihypertensive Therapy?

I would like to propose another possible mechanism that has been little considered, namely that rapid lowering of blood pressure in patients with left ventricular hypertrophy or coronary heart disease or both may, in some circumstances, be deleterious by compromising coronary perfusion.

Under normal circumstances, oxygen extraction from the coronary arteries is nearly maximal at rest. The principal means of increasing myocardial oxygen delivery is by increased flow. Therefore, in health, coronary flow can increase about five-fold. Increased myocardial oxygen demand promptly leads to a decrease in coronary vascular resistance and a corresponding increase in flow. This normal autoregulatory capacity is referred to as normal coronary reserve. (H14). In coronary heart disease, myocardium that is downstream from a hemodynamically significant narrowing of a large epicardial vessel has already signaled for a decrease in coronary arteriolar tone. Coronary reserve in that bed is diminished or even obliterated. Coronary reserve is also diminished in LVH. (B2,M6,P2,S3). The number of capillaries do not increase

to match the increased myocardial mass. Therefore, to maintain normal oxygen delivery, flow through the existing vessels must be increased. (B1,R2,M5,M6,P2). Furthermore, blood flow during maximal vasodilation may be diminished as a result of changes in the walls of the vessels. (M7,S4). In addition, distribution of blood flow between endocardium and epicardium is disturbed (M5). These pertubations in coronary reserve and blood flow characteristics favor development of myocardial ischemia and infarction, (M8) and when infarction occurs, larger size. (K7). In a canine model, infarction in the presence of LVH was more apt to result in ventricular fibrillation than in its absence. (K7).

In the presence of LVH or CHD, a certain coronary bed or the entire left ventricular myocardium might be dependent on a higher-than-normal perfusion pressure to maintain adequate oxygen delivery. Rapid lowering of the perfusion pressure without regression of LVH or amelioration of coronary stenoses could theoretically cause myocardial ischemia or infarction.

ARE ALL MEANS OF EQUAL BLOOD PRESSURE LOWERING OF EQUAL BENEFIT

IN PREVENTING CHD MORTALITY AND MORBIDITY?

A number of findings in recent years have raised the question of whether all means of lowering blood pressure to an equal degree are of equal benefit in preventing complications of hypertension, especially CHD endpoints. The two issues raised earlier about agents that alter serum lipids to a more atherogenic pattern and the relationship of diuretic therapy and VPDs are both germane to this discussion. A third important observation is that betablockers, at least those without intrinsic sympathomimetic activity, reduce the incidence of subsequent coronary events in survivors of MI (B3,H10,N1). A fourth finding is that LVH regression can be effected by some regimens, but not by others. It is a reasonable hypothesis that a treatment regimen that

leads to regression of LVH will be more effective in reducing coronary events than one that does not. Regression of LVH in man was shown as early as 1957 (H11) and has been confirmed many times. The effect on LVH regression is somewhat hard to sort out because many studies in man used multi-drug regimens. Nevertheless, animal and human investigations indicate that LVH regression can be effected by centrally active sympatholytics such as alpha methyl DOPA, (S5,S6,F1), peripherally active sympatholtics such as guanethidine (01), beta-blockers (W2,H12,T1,T2,C2), calcium antagonists (M9), and angiotensin-converting enzyme inhibitors. (N2,D4,S8,L1). Monotherapy with vasodilators does not cause LVH regression. (D5). Most of the data with diuretic therapy are a part of multi-drug regimens. It appears that monotherapy with diuretics also does not effect LVH regression. (D6,W3). It is noteworthy that there is a dissociation between the amount of blood pressure depression and the degree of LVH regression. (F1).

Comparison data in clinical trials to date are limited to beta-blockerbased therapy versus non-beta-blocker-based therapy (principally diuretics) in studies begun in the late 1970s. The possibility of a protective effect of beta-blockers against CHD endpoints in hypertension was given a stimulus by some observational findings in 1978 by the Gothenberg Primary Prevention Trial. (B4). A group of men with diastolic blood pressure greater than 115 mm Hg and who were treated in the hypertension clinic - mostly with betablockers as primary therapy followed by diuretics, vasodilators, and sympatholytics - had fewer coronary heart disease events than a control group of men with <u>less</u> severe hypertension who were not followed in hypertension clinic and whose hypertension was not treated, but who received the same anti-smoking and anti-hypercholesterolemic measures as the treated hypertensive cohort.

Table 8 shows the design features for the two trials for which extensive results have been published, the Medical Research Council of the U.K. trial (MRC) (M1) and the International Prospective Primary Prevention Study in Hypertension (IPPPSH). (I2). The MRC trial also had a placebo group (see above). The two studies were similar in several ways. The mean ages were identical, 52 years, and the age ranges were very close. Men composed about half of both trials. Both excluded advanced cardiac disease. IPPPSH was more conservative towards coronary heart disease; it excluded any such known disease altogether. The MRC admitted men with remote MI without angina. On the other hand, IPPPSH enrolled 18% of their patients with LVH-ECG compared to less than 1% in the MRC trial. This probably reflects the higher diastolic blood pressures in the IPPPSH subjects, 100-125 mmHg, than those of the MRC trial, 90-109 mm Hg. Both studies were very large. The MRC study included 8700 patients and 42,911 patient - years who received a beta-blocker-based or diuretic-based regimen. There were 6,557 patients and 25,651 patient - years The treatment protocols differed. Both had a beta-blocker based in IPPPSH. group, propranolol in the MRC and oxprenolol, a beta-blocker with intrinsic sympathomimetic activity, in IPPPSH. Secondary therapy for the beta-blocker group in the MRC trial was limited to alpha methyl DOPA but could be any other non-beta-blocker drug in IPPPSH. Sixty-seven percent received diuretics. Non-beta-blocker therapy in the MRC trial was the thiazide diuretic, bendrofluazide, as a first step. A sympatholytic could be added as a second In IPPPSH, only 15% received monotherapy with the placebo resembling step. oxprenolol. Supplementary drugs could include any non-beta-blocker agent. Eighty-two percent received diuretic therapy. As noted above, blood pressure reduction in the MRC trial was a bit disappointing. Thirty to forty percent of treatment patients had diastolic blood pressures above 90 mm Hg at each of

TABLE 8

MILD-TO-MODERATE HYPERTENSION AND CORONARY HEART DISEASE

DESIGN FEATURE OF TWO TRIALS COMPARING REGIMENS WITH AND WITHOUT BETA-BLOCKER

		MRC	IP	PPSH
	<i>c</i>	1985	19	85
Polulation age, range, mean		35-64, 52		40-64, 52
% men		52		50
Blood Pressure		90-109, D		100-125, D
Cardiac Disease Exclusions		CHF, MI within 3 mos., Angina		CHF, MI, Angina
LVH, Prevalence		0.3%		18%
Size, No.		8700*		6557
Patient years		42911*		25651
Years follow-up, range, mean		?-5, 4.9		3-5,?
Beta-Blocker Regimen [¶]	I.	Propranolol, up to 240	I.	Oxprenolol, 160 as monotherapy 30%
	II.	ADD AMD, ?	II.	Supplementary Drugs: diuretic 34%; sympatholytic 1.7%; vasodilator 1.3%; diuretic
				+ sympatholytic 14%; diuretic + vasodilator 10%; diuretic + sympatholytic + vasodilator 9%;
Non Beta-Blocker Regimen	I.	Bendrofluazide, 10	I.	Placebo as monotherapy, 15%
	п.	Add AMD, ? or add Guanethidine, ?	11.	Supplementary Drugs: diuretics 34%; sympatholytic 2%; vasodilator 0.9%; diuretic + sympatholytic 21%; diuretic +vasodilator 11%; diuretic +
Change in Diastolic BP				16%; sympatholytic + vasodilator 0.8%.
Beta-Blocker		ca9		-20
Non Beta-Blocker		ca10		-17
w - Marao C.	1	and the state of the state of the state		

* = These figures exclude the patients in this study on placebo.
¶ = All doses given in mg.
ABBREVIATIONS: Same as for Table 2.

the anniversary visits. Nevertheless, diastolic blood pressure was dropped an average of about 9 mm Hg with beta-blocker-based therapy and about 10 mm Hg with diuretic-based therapy. Diastolic blood pressure reduction was greater in IPPPSH, reflecting in part the higher average blood pressures at entry into the study. There was a 20 mm Hg drop with beta-blocker-based therapy and a 17 mm Hg drop with non-beta-blocker therapy.

The results of these trials in reducing CHD endpoints are outlined in Table 9. The results of both are remarkably similar. Overall, there was no significant difference between the two types of treatment, although there may be a slight trend favoring beta-blocker-based therapy. There is a difference between the sexes, however. There is no apparent difference between the two treatments for women, but there appears to be a trend favoring beta-blocker based therapy in men. Combining the results of men in both studies, all CHD endpoints were lower in the beta-blocker-based therapy: non-fatal MI by 15%, CHD death by 21%, and coronary events by 18%. The answer to the questions raised by the differences between the sexes appears to lie in interesting post hoc sub-group analyses of the results of smokers versus non-smokers. The MRC trial found that in non-smokers, the coronary event rate was reduced overall by a beta-blocker-based regimen compared to placebo but was not reduced at all by the diuretic-based-regimen compared to placebo. The protective effect was almost totally restricted to male non-smokers. Coronary events were rare and almost equal in non-smoking women regardless of treatment regimen. Similarly, in IPPPSH, male non-smokers fared significantly better on a regimen based on a beta-blocker than on one not including a beta-blocker. The trend favoring beta-blockers overall and especially in men can, therefore, be accounted for by a protective effect of beta-blockers against CHD endpoints in non-smoking, hypertensive men. These observations point out again the complexities of the interactions of the risk factors for CHD. An additional

		FINDIN	35 OF THO	TRIALS COMPARIN	ic recimens	WITH AND WITH	HOUT BELV	-BLOCKER				
		لور				WOMEN				MEN + WO	MON	
	No.	Rate *	No.	Non-BB Rate*	No.	RB Rate*	No.	-RB Rate*	No.	Rate*	Non-H	13 Rate*
uto Datal M		3										
IPPPSH	43	6.6	55	8.7	14	2.2	12	1.9	57	4.4	67	5.2
	C.		10	л	o	0	=	1	ፍ	2	5	ა თ
THE C	1		ł	Ť			1		L.		2	1.0
Cardiac Death												
IPPPSH	24	3.7	27	4.3	17	2.7	13	2.0	41	3.2	40	3.1
MRC	38	3.4	50	4.6	9	6.0	9	0.9	47	2.2	59	2.8
Total Coronary Event												
IPPPSH	67	10.3	82	13.0	31	4.9	25	3.9	86	7.6	107	8.4
MRC	85	7.6	99	9.0	18	1.8	20	1.9	103	4.8	119	5.6
No. of Subjects												
IPPPSH	1605		1589		1580		1583		3185		3172	
MRC	2285		2238		2118		2059		4403		4297	
Patient - Years												
IPPPSH	6508		6331		6368		6444		12876		13075	
MRC	11184	1	.0945		10508		10274		21692		21219	

٠

* = Rate per 1000 patient years.
ABBREVIATIONS: BB = beta blocker

28

TABLE 9

MILD TO MODERATE HYPERTENSION AND CORONARY HEART DISEASE

observation of the IPPPSH was that LVH-ECG resolved more quickly in the betablocker group than in the non-beta-blocker group.

FUTURE DIRECTIONS

In the next few years, it seems likely that the most rapid advances in our knowledge of cardioprotective effects of various antihypertensive regimens will come from anatomic, physiologic, and biochemical studies. In man, echocardiography, Doppler ultrasonography, and radionuclide ventriculography are being used with considerable success in studying the anatomical and physiological responses of the heart to hypertension and the results of treatment on the heart. I have already mentioned the use of echocardiography as a sensitive means of detecting left ventricular hypertrophy and its In recent years, attention has been given to systolic and regression. diastolic function of the heart in hypertension. Diastolic dysfunction appears to be the earliest detectable abnormality. (Q1,H13,F2,I3,D7,S1). Systolic dysfunction appears later and the earliest response of the heart to hypertension seems to be an enhanced contractile state. Investigation in the next few years should vastly increase our knowledge of the beneficial and deleterious effects on cardiac anatomy and function of different therapeutic interventions in different subsets of patients in the evolution of hypertensive heart disease. (Q1,H13,F2,I3,D7,S1,F3,S9,D8,H15,A2,F4,B6). Perhaps the best example of this so far is the recent discription of a syndrome in elderly hypertensive patients of extraordinary concentric LVH, supernormal systolic function, and marked diastolic dysfunction.(T3). All patients who received beta-blockers or calcium blockers obtained symptomatic relief, whereas half of the patients who received vasodilators experienced hypotensive complications, including one death.

Future research in both animal and human subjects should be able to

clarify several important issues, especially: (1) The rate of LVH regression with various pharmacologic interventions and (2) Whether various treatments that effect resolution of LVH are associated with resolution of diastolic dysfunction and improvement in coronary reserve and at what rate.

A CONCISE SUMMARY

Briefly summarized, considerable strides have been made in the last 20 years in our understanding of the relationship of hypertension to CHD endpoints. The major observations and conclusions, in my view, are as follows:

- Hypertension approximately doubles the risk of coronary events; hypertension plus LVH increases the risk about six-fold.
- 2. Treatment of mild-to-moderate hypertension reduces CHD end-points, but the observed reduction is rather small, about 10%, and thus difficult to demonstrate conclusively, even in large trials. The observed reduction, about one-fifth of the expected maximum benefit probably somewhat underestimates the real benefit, since the controlled intervention trials were of relatively short duration (1-8 years) and blood pressure reduction in the control groups was often greater than expected.
- 3. Reduction of CHD endpoints with treatment of hypertension is considerably less prominent than reduction in other hypertensive complications such as stroke, congestive heart failure, development of LVH, and accelerated hypertension. This probably owes in part to the dependency of coronary heart disease on multiple risk factors with complex interactions, while hypertension alone is the major risk factor for the other complications.
- 4. While part of the problem of demonstrating a positive effect on coronary events conclusively may lie in inadequate power of the studies, possible deleterious effects of antihypertensive therapy must be considered and include: (a) atherogenic changes in serum lipids with diuretics and many beta-blockers; (b) diureticinduced hypokalemia and increased VPDs; (c) increased coronary events in patients with abnormal ECGs, especially LVH, receiving antihypertensive therapy, especially high-dose diuretics. I propose that this

last possibility may be due to decreased coronary flow reserve and dependency of coronary perfusion on a certain critical perfusion pressure.

5. All means of equal blood pressure lowering are not equally cardioprotective. Prevention of LVH development and regression of established LVH is effected by betablockers, sympatholytics, calcium antagonists, and angiotension converting enzyme inhibitors, but not by vasodilators alone and probably not by diuretics alone. An antihypertensive regimen including beta-blocker reduces the likelihood of coronary events in non-smoking men more than a regimen that does not include a betablocker, but does not clearly do so in women or men who smoke. Major advances in this area should come in the next few years in hypertensive subjects with noninvasive study of cardiac anatomy and systolic and diastolic function.

CONCLUSIONS AND RECOMMENDATIONS

In formulating recommendations, I have relied heavily on the 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. (J1,J2). But that report was prepared in final form in February, 1984 and many of the data reviewed here have been published since then. Therefore, I will take the reviewers perogative to differ on some points. In view of the limited scope of this review, my recommendations will be largely restricted to treatment of hypertension for prevention of CHD mortality and morbidity.

My first conclusion, a cautious one, is that antihypertensive therapy for patients with mild-to-moderate hypertension, probably does reduce CHD mortality and morbidity, but only slightly by approximately 10%.

A second conclusion, also a cautious one, is that antihypertensive therapy appears to be substantially more effective in preventing CHD endpoints if therapy is begun <u>before</u> rather than after cardiac damage, especially LVH. Such an interpretation of the data are inconsistent with the recommendations favored by some, that therapy for mild-to-moderate hypertension be held until there is evidence of end-organ damage.

The Joint National Committee recommended pharmacological therapy for patients with persistent elevation of diastolic blood pressure above 95 mm Hg and for those with diastolic blood pressures of 90-94 mm Hg, aged 50 or older or with other risk factors present for CHD or any evidence of target organ damage. For low-risk patients younger than 50 years and with pressures 90-94 mm Hg, they recommended initial non-pharmacological therapy such as weight reduction, a prudent isotonic exercise program, salt restriction, and biofeedback therapy. They noted the current controversies about initiating pharmacological therapy in patients in this least group when non-pharmacologic therapy fails to lower the blood pressure below 90 mm Hg. It would require a study of enormous magnitude and cost to specifically address this issue for an effect on CHD endpoints. I find it hard to reach a conclusion on this issue. Data from HDFP and overall data suggesting better results for preventive rather than remedial therapy favor beginning drug treatment. But in a group with low risk for CHD, if one chooses drug therapy it is imperative to choose a regimen very carefully, avoiding one that would increase the risk of CHD endpoints as much or more than slight blood pressure depression would decrease them. Patients not receiving drug therapy should be observed carefully. Many will progress to higher blood pressures.

A fourth conclusion is that an antihypertensive regimen chosen to prevent CHD endpoints should be one that has been shown to prevent LVH and cause its regression, and therefore should include a beta-blocker or other sympatholytic agent, angiotensin converting enzyme inhibitor, or calcium blocker.

A fifth conclusion is that an antihypertensive regimen should include a beta-blocker in non-smoking men, unless otherwise contraindicated.

A sixth conclusion is that high-dose diuretics should be avoided whenever possible to avoid increases in frequency and complexity of VPDs, especially in

patients with known or suspected cardiac disease.

A final conclusion is that it may be prudent to commence treatment in patients with LVH-ECG very carefully and with frequent observation, lowering the blood pressure gradually over a number of months and initiating therapy with a well-selected regimen for each given patient including an agent that can effect regression of LVH. It is not yet been proved that regression of LVH is a beneficial goal, but such an outcome seems likely and there is no cogent reason to think regression of LVH is deleterious. Therefore, in my view, regression of LVH in therapy of hypertension should be a goal of current therapy for patients with LVH. Similar care appears prudent for commencing therapy for the patient with coronary heart disease, especially those with ECG abnormalities. Their regimen should include agents that also prevent or mitigate myocardial ischemia, such as beta-blockers or calcium blockers. During initiation of therapy, careful follow-up is prudent to watch for any evidence of worsened ischemia.

The clinical trials reviewed this morning did not unambiguously answer all the questions that they raised, but they raised several additional new hypothesis as often happens with such trials. These trials were conducted concurrent with development of new technologies to study the heart and new antihypertensive drugs. Work in the next few years should greatly enhance our understanding of how to protect hypertensive patients from the toll of coronary heart disease.

References

A1. Amery A, Brixko P, Clement D, DeSchaepdryver A, Fagard R, Forte J, Henry JF, Leonetti G, O'Malley K, Strasser T, Birkenhager W, Bulpitt C, Dallery C, Forette F, Hamdy R, Joosens JV, Lund-Johansen P, Petrie J, Tuomilehto J: Mortality and Morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1:1349-1954.

A2. Abi-Samra F, Fouad FM, Tarazi RC: Determinants of left ventricular hypertrophy and function in hypertensive patients. Am J Med: 1983;75(Suppl 3A) 26-32.

B1. Breisch EA, Houser Sr, Corey RA, Spann JF, Bove AA: Myocardial blood flow and capillary density in chronic pressure overload of the feline left ventricle. Cardiovasc Res 1980; 14:469-475.

B2. Ball RM, Bache RJ, Cobb FR, Greenfield JC Jr: J Clin Invest 1975; 55:43-49.

B3. Beta-Blocker Heart Attack Trail Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247:1707-1714.

B4. Berglund G, Sannerstedt R, Andersson O, Wedel H, Wilhelmsen L, Hansson L, Sivertsson R, Wikstrand J: Coronary heart disese after treatment of hypertension. Lancet 1978; 1:1-5.

B5. Brodsky M, Wu D, Denes P, Kanakis C, Rosen KM: Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol, Mar 1977; 39:390-5.

B6. Borer JS, Jason M, Devereux RB, Fisher J, Green M, Bachrach SV, Pickering T, Laragh JH: Function of the hypertrophied left ventricle at rest and during exercise: Hypertension and aortic stenosis. Am J Med 1983 75(Suppl 3A): 34-39.

C1. Casale PN, Devereaux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.

C2. Corea L, Bentivoglio M, Verdecchia P, Provvidenza, Motolese M: Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol. Int J Clin Pharmacol Ther Toxicol 1984; 22:365-370.

D1. Devereux RB, Phillips MC, Casale PN, Eisenberg RR, Kligfield P: Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determination of left ventricular mass as the reference standard: comparison of standard criteria, computer diagnosis and physician interpretation. J Am Coll Cardiol 1984; 3:82-87.

D2. Devereaux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55:613-618.

D3. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.

D4. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin J, Frohlich ED: Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53:105-108.

D5. Drayer JIM, Gardin JM, Weber MA, Aronow WS: Cardiac muscle mass during vasodilator therapy of hypertension. Clin Pharmacol Ther 1983; 33:727-732.

D6. Drayer JIM, Gardin JM, Weber MA, Aronow WS: Increases and decreases in ventricular septal thickness during diuretic therapy. Clin Pharm Ther 1982; 32:283-288.

D7. Dunn FB, Chandraratna P, DeCarvalho JGR, Basta LL, Frohlich ED: Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 39:789-795.

D8. Dunn FG, Oigman W, Sungaard-Rusek, Messerli FH, Ventura H, Reisen E, Frohlich ED: Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexes. J Am Coll Cardiol 1983; 1:1348-1351.

F1. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE: Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa: Lack of association with blood pressure control. Am J Cardiol 1982; 49:795-801.

F2. Fouad FM, Tarazi RC, Gallager JH, McIntyre WJ, Cook SA: Abnormal left ventricular relaxation in hypertensive patients. Clin Sci 1980; 59:411s-414s.

F3. Fouad FM, Slominski M, Tarazi RC: Left ventricular diastolic function in hypertension: Relationship to left ventricular mass and systolic function. JACC 1984; 3:1498-1506.

F4. Francis CK, Cleman M, Berger HJ, Davies RA, Giles RW, Black HR, Vita N, Zito RA, Zaret BL: Left ventricular systolic performance during upright bicycle exercise in patients with essential hypertension. Am J Med 1983; 75(Suppl 3A): 40-46.

G1. Grimm RH, Cohen JG, Smith WM, Falvo-Gerard L. Neaton JD, and the Multiple Risk Factor Trial Research Group: Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT): Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med 1985; 145:1191-1199.

G2. Greenberg G, Brennan PJ, Miall WE: Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial.

H1. Helgeland A: Treatment of mild hypertension: A five year controlled drug trial. Am J Med 1980; 69:725-732.

H2. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242:2562-2571.

H3. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race-sex and age. JAMA 1979; 242:2572-2577.

H4. Hypertension Detection and Follow-up Program Cooperative Group: The effect of treatment on mortality in "mild" hypertension: Results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982; 307:976-980.

H5. Hypertension Detection and Follow-up Program Cooperative Group: Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-up program. Hypertension 1984; 6(Suppl I): I-198-I-206.

H6. Holland OB, Nixon JV, Wuhnert B: Diuretic-induced ventricular ectopic activity. Am J Med 1981; 70:762-768.

H7. Hollifield JW, Slaton PE: Cardiac arrhythmias associatd with diuretic induced hypokalaemia and hypomagnasaemia: R Soc Med Int Cong Symp Ser 1980; 44:17-26.

H8. Hypertension Detection and Follow-up Program Cooperative Research Group: The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. Circulation 1984; 70:996-1003. H9. Holme I, Helgeland A, Hjermann I, Leren P, Lund-Larsen PG: Treatment of mild hypertension with diuretics: The importance of ECG abnormalities in The Oslo Study and in MRFIT. JAMA 1984, 251: 1298-1299.

H10. Hjalmarson A, Herlitz J. Holmberg S, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Welhelmsen L, Wilhelmsson C: The Goteberg Metoprolol Trial: Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983: 67(Suppl I): I-26-I-32.

H11. Helmcke JG, Schnickloth R, Corcoran AC: Am Heart J 1957; 53:549-557.

H12. Hill LS, Monaghan M, Richardson PJ: Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol 1979; 7(Suppl 2): 256s-259s.

H13. Hanrath P, Mathey DG, Siegert R, Bleifeld W: Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: an echocardiographic study. Am J Cardiol 1980; 45:15-23.

H14. Hoffman JIE: Maximal coronary flow and the concept of coronary vascular reserve. Circulation 1984; 70:153-9.

Hl5. Hartford M, Wikstrand JCM, Wallentin J, Ljungman SMG, Berglund GL: Left ventricular wall stress and systolic function in untreated primary hypertension. Hypertension 1985; 7:97-104.

I1. Ibrahim MM, Madkour MA, Mossaliam R; Factors influencing cardiac hypertrophy in hypertensive patients. Clin Sci 1981; 61:105s-108s.

I2. IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension 1985; 3:379-392.

I3. Inouye I, Massie B, Loge D, Topic N, Silverstein D, Simpson P, Tubau J: Abnormal left ventricular filling: An early finding in mild to moderate systemic hypertension. Am J Cardiol 1984; 53:120-126.

I4. Inouye IK, Massie BM, Loge D, Simpson P, Tuban JF: Failure of antihypertensive therapy with diuretic, beta -blocking and calcium-blocking drugs to consistently reverse left ventricular diastolic filling abnormalities. Am J Cardiol 1984; 1583-1587. J1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med 1984; 144:1045-1057.

J2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: Hypertension prevalence and the status of awareness, treatment, and control in the United States: Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 1985; 7:457-468.

K1. Kannel WB, Schwartz MJ, McNamara PM: Blood pressure and risk of coronary heart disease: The Framingham Study. Dis Chest 1969; 56:43.

K2. Kannel WB, Wolf PA, Verter J, McNamara PM: Epidemiologic assessment of the role of blood pressure in stroke: The Framingham Study. JAMA 1970; 214:301-10.

K3. Kannel WB, Castelli WP, McNamara PM, McKee A, Feinleib M: Role of blood pressure in the development of congestive heart failure: The Framingham Study. N Engl J. Med 1972; 287:781.

K4. Kannel WB: The role of blood pressure in cardiovascular morbidity and mortality. Prog. Cardiovasc Dis 1974; 17:5.

K5. Kannel WB, Gordon T, Castelli WP, Margolis JR: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: The Framingham Study. Ann Intern Med 1970; 72:813-822.

K6. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75(Suppl 3A): 4-11.

K7. Koyanagi S, Eastman CL, Harrison DG, Marcus ML: Circ Res 1982; 50:55-62.

L1. Lombardo M, Zaini G, Pastori F, Fusco M, Pacini S, Foppoli C. Left ventricular mass and function before and after antihypertensive treatment. Hypertension 1983: 1:215-219.

M1. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985; 291:97-104.

M2. Management Committee: The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980; 1:1262-1267.

M3. Multiple Risk Factor Intervention Trail Research Group: Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 1982; 248:1465-1477. M4. Medical Research Council Working Party on Mild to Moderate Hypertension: Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial. Br Med J 1983; 287:1249-1253.

M5. Mueller TM, Marcus ML, Kerber RE, Young JA, Barnes RW, Abboud FM: Effect of renal hypertension and left ventricular hypertrophy on the coronary circulation in dogs. Circ Res 1978; 42:543-549.

M6. Mittman U, Bruckner UB, Keller HE, Kohler U, Vetter H, Waag KL: Myocardial flow reserve in experimental cardiac hypertophy. Basic Res Cardiol 1980; 75:199-206.

M7. Mark AL: Structual changes in resistance and capacitance vessels in borderline hypertension. Hypertension 1984; 6(Suppl III): III-69-III-73.

M8. Mueller TM, Tomanek RJ, Kerber RE, Marcus ML: Myocardial infarction in dogs with chronic hypertension and left ventricular hypertrophy. Am J Physiol 1980; 239:H731-H735.

M9. Muiesan G, Agabiti-Rosei E, Romanelli G, Muiesan ML, Castellano M, Beschi M: Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986; 57:44D-49D.

N1. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving myocardial infarction. N Engl J Med 1981; 304:801-807.

N2. Nakashima Y, Fouad FM, Tarazi RC: Regression of left ventricular hypertrophy from systemic hypertension by enalopril. Am J Cardiol 1984: 53:1044-1049.

01. Ostman-Smith I: Cardiac Sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci 1981; 61:265-272.

P1. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: Final report of the Pooling Project. J Chronic Dis 1978; 31:201-306.

P2. Pichard AD, Gorlin R, Smith H, Ambrose J, Meller J: Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type. Evidence for an impaired coronary vascular reserve. Am J Cardiol 1981; 47:547-554.

Q1. Qureshi S, Wagner HN, Alderson PO, Housholder EF, Douglas KH, Lotte MG, Nickoloff EL, Tanabe M, Knowles LG: Evaluation of left ventricular function in normal persons and patients with heart disease. J Nucl Med 1978; 19:135-141.

Rl. Reichek N, Devereux RB. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic, and electrocardiographic findings. Circulation 1981: 63:1391-1398.

R2. Rembert JC, Kleinman LH, Fedor JM, Wechsler AS, Greenfield JC Jr: Myocardial blood flow distribution in concentric left ventricular hypertrophy. J Clin Invest 1978; 62:379-386.

R3. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S: Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297:750-757.

S1. Savage DD, Drayer JIM, Henry WL, Mathews EC Jr, Ware JH, Gardin JM, Cohen ER, Epstein SE, Laragh JH: Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979; 59:623-632.

S2. Smith WM for the U.S. Public Health Service Hospitals Cooperative Study Group for the Treatment of mild hypertension: Results of a ten-year intervention trial. Circ Res (Suppl I) 1977;40: I-98 - I-105.

S3. Strauer BE: The coronary circulation in hypertensive heart disease. Hypertension 1984: 6(Suppl III): III-74 - III-80.

S4. Sivertsen R: Structural adaptations in borderline hypertension. Hypertension 1984; 6(Suppl III): III-103 - III-107.

S5. Sen S, Tarazi RC, Bumpus FM: Biochemical changes associated with development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Cardiovas Res 1976; 10:254-261.

S6. Sen S, Tarazi RC, Bumpus FM: Cardiac Hypertrophy and antihypertensive therapy. Cardiovas Res 1977; 427-433.

S7. Sen S: Regression of Cardiac hypertrophy: Experimental animal model. Am J Med 1983; 75(Suppl 3A): 87-93.

S8. Sen S, Tarazi RC, Bumpus FM: Effect of converting enzyme inhibitor (SQ 14225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980; 2:169-176.

S9. Smith V-E, White W, Meeran MK, Karimeddini MK: Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension. JACC 1986; 8:1449-1454.

T1. Trimarco B, Ricciardelli B, Volpe M, et al. Curr Ther Res 1980; 28:953-963.

T2. Trimarco B, Wikstrand J: Regression of cardiovascular structural changes by antihypertensive therapy. Hypertension

1984; 6(Suppl III): III-150 - III-157.

T3. Topol EJ, Traill TA, Fortuin NJ: Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312:277-283.

V1. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143-1152.

V2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972: 45:991-1004.

V3. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:1028-1034.

W1. Woythaler JN, Singer SL, Kwan OL, Meltzer RS, Reubner B, Bommer W, DeMaria A: Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: Comparison with postmortem mass measurements. J Am Coll Cardiol 1983; 2:305-311.

W2. Weiss L, Lundgren Y, Folkow B: Effects of prolonged treatment with adrenergic beta-receptor antagonists on blood pressure, cardiovascular design and reactivity in spontaneously hypertensive rats (SHR). Acta Physiol Scand 1974; 91:447-457.

W3. Wollam GL, Hall WD, Porter VD, Douglas MB, Unger DJ, Blumenstein BA, Cotsonis GA, Knudtson ML, Felner JM, Schlant RC: Time Course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med: 75(Suppl 3A): 100-110.

W4. Wikstrand J: Diastolic function of the hypertrophied left ventricle in primary hypertension. Clinical Physiology 1986; 6:115-127.

W5. Weinberger MH: Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med 1986; 80(Suppl 2A):64-70.